PMID- 32806719
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 8
DP  - 2020 Aug 12
TI  - Anti-cancer Immunotherapies Targeting Telomerase.
LID - 10.3390/cancers12082260 [doi]
LID - 2260
AB  - Telomerase is a reverse transcriptase that maintains telomeres length, 
      compensating for the attrition of chromosomal ends that occurs during each 
      replication cycle. Telomerase is expressed in germ cells and stem cells, whereas 
      it is virtually undetectable in adult somatic cells. On the other hand, 
      telomerase is broadly expressed in the majority of human tumors playing a crucial 
      role in the replicative behavior and immortality of cancer cells. Several studies 
      have demonstrated that telomerase-derived peptides are able to bind to HLA (human 
      leukocyte antigen) class I and class II molecules and effectively activate both 
      CD8(+) and CD4(+) T cells subsets. Due to its broad and selective expression in 
      cancer cells and its significant immunogenicity, telomerase is considered an 
      ideal universal tumor-associated antigen, and consequently, a very attractive 
      target for anti-cancer immunotherapy. To date, different telomerase targeting 
      immunotherapies have been studied in pre-clinical and clinical settings, these 
      approaches include peptide vaccination and cell-based vaccination. The objective 
      of this review paper is to discuss the role of human telomerase in cancer 
      immunotherapy analyzing recent developments and future perspectives in this 
      field.
FAU - Negrini, Simone
AU  - Negrini S
AD  - Internal Medicine, Clinical Immunology and Translational Medicine Unit, IRCCS 
      Ospedale Policlinico San Martino, 16132 Genoa, Italy.
AD  - Centre of Excellence for Biomedical Research and Department of Internal Medicine, 
      University of Genoa, 16132 Genoa, Italy.
FAU - De Palma, Raffaele
AU  - De Palma R
AD  - Internal Medicine, Clinical Immunology and Translational Medicine Unit, IRCCS 
      Ospedale Policlinico San Martino, 16132 Genoa, Italy.
AD  - Centre of Excellence for Biomedical Research and Department of Internal Medicine, 
      University of Genoa, 16132 Genoa, Italy.
FAU - Filaci, Gilberto
AU  - Filaci G
AD  - Centre of Excellence for Biomedical Research and Department of Internal Medicine, 
      University of Genoa, 16132 Genoa, Italy.
AD  - Biotherapy Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200812
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7465444
OTO - NOTNLM
OT  - cancer
OT  - clinical trials
OT  - hTERT
OT  - immunotherapy
OT  - telomerase
OT  - vaccine
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/19 06:00
MHDA- 2020/08/19 06:01
PMCR- 2020/08/12
CRDT- 2020/08/19 06:00
PHST- 2020/07/13 00:00 [received]
PHST- 2020/08/05 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/08/19 06:01 [medline]
PHST- 2020/08/12 00:00 [pmc-release]
AID - cancers12082260 [pii]
AID - cancers-12-02260 [pii]
AID - 10.3390/cancers12082260 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Aug 12;12(8):2260. doi: 10.3390/cancers12082260.